Glucose Laboratoire Aguettant

Glucose Laboratoire Aguettant is an intravenous solution containing glucose monohydrate as the active ingredient; the product is supplied in a typical concentration, though specific strength is not disclosed, and is marketed within the European Union. It is classified as an excipient rather than a therapeutic drug and is intended for use by healthcare professionals in hospitals or infusion centers to provide carbohydrate energy during intravenous therapy.

Glucose Laboratoire Aguettant is used as an intravenous carbohydrate source to maintain blood glucose levels and provide energy during various medical procedures. It is commonly employed in the following clinical situations: - During surgery or anesthesia to prevent hypoglycemia. - In patients receiving parenteral nutrition who require a glucose supply. - For correction of low blood sugar in acute care settings. - As a diluent or carrier for compatible intravenous medications. - In pediatric or neonatal care where glucose provision is essential.

When administered intravenously, glucose solutions can produce a range of physiological responses. Reported effects are grouped into common and serious categories.

Common: - Transient increase in blood glucose concentration. - Mild electrolyte shifts, particularly sodium and potassium. - Local irritation or discomfort at the infusion site. - Nausea or mild abdominal discomfort.

Serious: - Hyperglycemia leading to osmotic diuresis. - Severe allergic reaction such as anaphylaxis, though rare.

Glucose Laboratoire Aguettant should be administered with attention to patient-specific factors and clinical context. Key precautions include: - Verify patient’s blood glucose level before infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency. - Avoid rapid infusion in neonates and infants. - Monitor electrolytes, especially sodium and potassium, during prolonged use. - Use aseptic technique to prevent contamination of the solution. - Discontinue if signs of hypersensitivity or severe hyperglycemia develop.

Glucose solutions may interact with other intravenous agents or affect the pharmacokinetics of certain medications. Interactions are categorized as follows:

Avoid: - Concurrent administration with high‑dose insulin without appropriate monitoring. - Co‑infusion with potassium chloride solutions that could precipitate. - Mixing with medications that are incompatible with dextrose solutions (e.g., certain antibiotics).

Use with caution: - Patients receiving diuretics, as shifts in fluid balance may be amplified. - Individuals on beta‑blockers, which can mask hypoglycemia symptoms.